Results from a double-blind phase 2 clinical study show that finafloxacin was a more effective and safe option than ciprofloxacin for the treatment of complicated urinary tract infections and acute pyelonephritis. This research is being presented at ASM's 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).
Data from the study shows that patients treated with a five-day course of finafloxacin had a higher, more rapid and more sustained level of pathogen eradication and improved clinical outcomes than those treated with the current standard of care, ciprofloxacin taken twice daily for 10 days.
"Finafloxacin was found to be both safe and tolerable and could offer physician a viable additional option when treating bacterial infections in future," says David Dally, CEO of MerLion Pharmaceuticals Pte. Ltd.
225 adult patients diagnosed with cUTI and acute pyelonephritis at 18 sites in Poland and Germany were randomized to receive 800 mg finafloxacin once daily either for a total of five or 10 days, or 400 mg (oral)/500 mg (iv) ciprofloxacin twice daily for 10 days. Physicians could switch from the initial intravenous to oral administration and release the patients from hospital after day 3.
Finafloxacin dosed for five days was as efficient as finafloxacin dosed for 10 days in a combined evaluation of the clinical and microbiological response with efficacy rates of 70 percent and 68 percent on day 17 of the study. Both finafloxacin dosing regimens were more efficient than the treatment with ciprofloxacin for 10 days resulting in 57 percent efficacy. The short five-day treatment period with finafloxacin did not result in an increased rate of relapses when compared to both 10-day treatment regimens in this study.
Furthermore, an interim evaluation on day 3 of the study revealed that finafloxacin eradicated pathogens more quickly than ciprofloxacin (89 percent vs. 79 percent). This rapid antibacterial activity of finafloxacin was not affected by urine pH, with comparable activity at acidic, neutral and basic conditions whereas ciprofloxacin eradicated pathogens less efficiently in patients with acidic urine.
"In contrast to ciprofloxacin, finafloxacin also showed a very rapid antimicrobial effect against ciprofloxacin-resistant pathogens and ESBL producing bacteria," says Dally. Resistance to fluoroquinolones and ESBL producing bacteria that cause UTIs in particular are an increasing health problem.
Urinary tract infections (UTIs) are among the most prevalent infectious diseases in ambulatory and hospitalized populations, with a substantial financial burden on society, causing more than 7 million annual physician visits in the U.S.
The results of this phase 2 clinical study were presented by MerLion Pharmaceuticals, a biopharmaceutical company based in Singapore and Berlin.
This research was presented as part of ASM's Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) being held Sept. 17-21, 2015 in San Diego.
Source: American Society for Microbiology
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.